SEOVF : Summary for SERNOVA CORP - Yahoo Finance

U.S. Markets closed

Sernova Corp. (SEOVF)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.19+0.00 (+0.79%)
At close: 10:59AM EDT
People also watch
SVA.VRVXCFRPMGFORGSRGRX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.19
Open0.19
Bid0.00 x
Ask0.00 x
Day's Range0.19 - 0.19
52 Week Range0.18 - 0.31
Volume2,200
Avg. Volume2,761
Market Cap31.73M
BetaN/A
PE Ratio (TTM)-19.16
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Marketwired4 months ago

    Sernova to Present Corporate and JDRF-Sponsored Clinical Trial Update at the Biotech Showcase(TM) 2017 Healthcare Conference in San Francisco

    Sernova Corp. , a clinical stage regenerative medicine company, is pleased to announce that Dr. Philip Toleikis, Sernova's President and CEO, will present an update on the company's corporate and business ...

  • PR Newswire6 months ago

    Sernova and CTI Clinical Trial Announce Regulatory Collaboration

    LONDON, Ontario, Nov. 2, 2016 /PRNewswire/ -- Sernova Corp. (SVA.V) (SEOVF) (PSH.F), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia and CTI Clinical Trial and Consulting Services (CTI), are pleased to announce their collaboration on regulatory matters respecting Sernova's Cell Pouch System(TM), a novel implantable and scalable medical device that when combined with therapeutic cells, may provide a convenient, safe and effective long-term therapeutic option for patients with chronic diseases such as insulin-dependent diabetes who seek to improve their quality of life. CTI as an expert in cell therapy, and immunology among other life-changing therapies in critically and chronically ill patients is supporting Sernova's clinical trial regulatory processes including submission of Sernova's regulatory package with the FDA for the recently announced JDRF supported clinical trial in patients with insulin-dependent diabetes.

  • Marketwired6 months ago

    Sernova and CTI Clinical Trial Announce Regulatory Collaboration

    Sernova Corp. , a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia and CTI Clinical Trial ...